Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.41 |
| ▸ | EIF4E | P06730 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220075 | 0.91 | F2RL3 (0.46) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL219651 | 0.91 | F2RL3 (0.46) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL221270 | 0.88 | F2RL3 (0.47) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13470875 | 0.88 | F2RL3 (0.50) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2576213 | 0.87 | F2RL3 (0.40) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2576091 | 0.85 | SIRT1 (0.46) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL220082 | 0.85 | F2RL3 (0.50) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27736269 | 0.85 | F2RL3 (0.47) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL219491 | 0.83 | SIRT1 (0.51) | F2RL3HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2572148 | 0.83 | SIRT1 (0.44) | F2RL3SIRT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167510-B1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2167510-B1 | SIRTUIN MODULATING IMIDAZOTHIAZOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| CN-101316853-B | Benzothiazole and thiazolopyridine as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC | 2014-09-24 | — | — | CN | disclosed |
| CN-103145738-A | Imidazo [2,1-b] thiayole derivatives as SIRTUIN modulating compounds | SIRTRIS PHARMACEUTICALS INC | 2013-06-12 | — | — | CN | disclosed |
| CN-101874031-B | Sirtuin-modulating imidazothiazole compounds | SIRTRIS PHARMACEUTICALS INC | 2013-02-20 | — | — | CN | disclosed |
| EP-1910362-B1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1910362-B1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1910384-B1 | IMIDAZO [2,1-B]THIAZOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-1910384-B1 | IMIDAZO [2,1-B]THIAZOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8247565-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | F2RL3 3049/4885HDAC3 5/4885HDAC4 14/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | F2RL3 2464/4885HDAC3 10/4885HDAC4 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.